Medaxes Sets Out Hopes For Belgian Biosimilars Taskforce
INAMI Taskforce Met For The First Time In Late January
Belgian off-patent industry association Medaxes has set out its aspirations for a new biosimilars taskforce that has been set up by local health insurance body INAMI. Data cited by the industry body shows that biosimilar penetration in Belgium is still lagging behind that of its European neighbors.
You may also be interested in...
Attendees to Medicines for Europe’s virtual summit on biosimilars heard how learning from experiences across Europe can allow individual countries to build a toolbox of policies to help create a sustainable biosimilars market.
Belgian industry association Medaxes has appointed a new board at the same time as revealing plans for a biosimilars awareness day in April, following in the footsteps of a recent initiative focused on generics.
Legislation that has just been adopted by the Belgian parliament is aiming to tackle shortages by requiring companies to notify local authorities of supply interruptions within three working days, as well as giving pharmacists the option to substitute equivalent alternatives to products in short supply. The new measures limit the risk of excessive sanctions for suppliers, according to local industry association Medaxes.